Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Chung HH, Morjaria S, Frame J, Riley M, Zhang AW, Martin SC, et al. Rethinking the need for a platelet transfusion threshold of 50 × 10 /L for lumbar puncture in cancer patients. Transfusion. 2020;60(10):2243-2249.

Sung S, Heymann JJ, Crapanzano JP, Moreira AL, Shu C, Bulman WA, et al. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. J Am Soc Cytopathol. 2020;9(5):332-345.

Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034-1045.

Racine-Brzostek SE, Asmis LM. Assessment of platelet function utilizing viscoelastic testing. Transfusion. 2020;60 Suppl 6:S10-S20.

Shukla SK, Carter TC, Ye Z, Pantrangi M, Rose WE. Modeling of Effective Antimicrobials to Reduce Staphylococcus aureus Virulence Gene Expression Using a Two-Compartment Hollow Fiber Infection Model. Toxins (Basel). 2020;12(2).

Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-, Alesi N, et al. Correction: p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2020;80(23):5424.

Yang Y, Sharma PD, Nair V, Jhaveri KD, Malieckal DA, Wanchoo R, et al. Kidney oxalate crystal deposition in adult patients: A relatively common finding . Clin Nephrol. 2020;93(5):243-250.

Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, et al. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer. Clin Cancer Res. 2020;26(22):6003-6016.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, et al. Loss with Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2020;203(2):344-350.

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? Haematologica. 2020;105(6):e276-e279.